AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...
It’s goodbye needles as you can keep the flu away with a nasal spray as the US Food and Drug Administration (FDA) has approved AstraZeneca’s FluMist for home use. It can be self-administered by adults ...